Diuretics

PreclinicalSmall molecule

Boehringer Ingelheim

Diuretics is one of 50 small molecule programs targeting Safety and Efficacy. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Safety and EfficacyCompleted

Safety and EfficacyPreclinical

Completed

Competition

Competitive Landscape

149 competitors in Safety and Efficacy

#DrugCompanyPhaseTrials

Rituxan

Roche

Phase 3

8 2

Opdivo

Bristol-Myers Squibb

Phase 3

7 3

Humira

Novartis

Phase 3

3 4

Avastin

Roche

Phase 3

3 5

BEYFORTUS

Sanofi

Phase 3

1 6

Neulasta

Amgen

Phase 3

1 7

Adriamycin

Pfizer

Phase 3

1 8

Oncovin

Eli Lilly

Phase 3

1 9

Cytoxan

BBaxter Healthcare Corporation

Phase 3

6 10

Rayos

RRoxane Laboratories

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Heart Failure3 trials

Cardiorenal Interactions During Treatment of Acute Decompensated Heart Failure: Diuretics Versus Ultrafiltration

Completed·UUniversity Hospital, Ghent·Phase 3·NCT01138683·1 enrolled

Evaluation of Heart Failure Treatment Guided by N-terminal Pro B-type Natriuretic Peptide (NTproBNP) vs Clinical Symptoms and Signs Alone

Completed· AstraZeneca logo

AstraZeneca·Phase 4·NCT00391846·252 enrolled

ELEVATE Early LEvosimendan Vs Usual Care in Advanced Chronic hearT failurE

Terminated·NNiguarda Hospital·Phase 3·NCT01290146·13 enrolled

Hypertension2 trials

Effect of Caldine® on Renal Function in Balanced Hypertension

Terminated· Boehringer Ingelheim logo

Boehringer Ingelheim··NCT02240641·5,417 enrolled

Hypertension Detection and Follow-up Program (HDFP)

Completed·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 3·NCT00000485

Critically Ill Patients1 trial

Effects of Fluid Balance Control in Critically Ill Patients

Completed·—·N/A·NCT02765009·1,411 enrolled

Heart Disease1 trial

Multiple Risk Factor Intervention Trial for the Prevention of Coronary Heart Disease (MRFIT)

Completed·UUniversity of Minnesota·Phase 3·NCT00000487

Safety and Efficacy1 trial

To Study the Safety and Efficacy of Midodrine With Albumin Versus Albumin Alone in Hepatic Hydrothorax

Completed·IInstitute of Liver and Biliary Sciences, India·N/A·NCT03645642·8 enrolled

7 more indications

CAR1 trial

Feasibility of an Integrated Patient Care (IPC) System Using Daily Filling Pressures

Completed·MMedtronic Cardiac Rhythm and Heart Failure·Phase 2·NCT01370564·21 enrolled

Sleep Apnea1 trial

Effect of Antihypertensive Agents Over Sleep Apnea

Completed·HHospital de Clinicas de Porto Alegre·Phase 3·NCT01896661·53 enrolled

Angiotensin Receptor Blockers1 trial

The Use of Angiotensin Receptor Blockers and the Risk of Cancer

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim··NCT02215733·1,165,781 enrolled

Critical Care1 trial

Mean Systemic Filling Pressure Continuous Diuretics Critical Care Patients

Completed·CCatharina Ziekenhuis Eindhoven··NCT03395951·18 enrolled

Ascites1 trial

Empagliflozin as a Novel Therapy in Refractory Ascites

Completed·—·Phase 2/3·NCT05430243·42 enrolled

Cirrhosis1 trial

Human Albumin for the Treatment of Ascites in Patients With Hepatic Cirrhosis

Completed·UUniversity of Bologna·Phase 4·NCT01288794·431 enrolled

AL amyloidosis1 trial

Epigallocatechingallate (EGCG) in Cardiac AL Amyloidosis

Terminated·FFondazione IRCCS Policlinico San Matteo di Pavia·Phase 2·NCT01511263·86 enrolled

Sources

References

[1]
ClinicalTrials.gov — 15 trial records for Diuretics. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Diuretics compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Diuretics. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Boehringer Ingelheim company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: Boehringer Ingelheim

Diuretics

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Heart Failure3 trials

Hypertension2 trials

Critically Ill Patients1 trial

Heart Disease1 trial

Safety and Efficacy1 trial

CAR1 trial

Sleep Apnea1 trial

Angiotensin Receptor Blockers1 trial

Critical Care1 trial

Ascites1 trial

Cirrhosis1 trial

AL amyloidosis1 trial

References

Drug Info

Quick Facts

Related News